Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013

Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom

(2015) Jean L. Mbisa et al.   CLINICAL INFECTIOUS DISEASES

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

(2015) L. Marije Hofstra et al.   CLINICAL INFECTIOUS DISEASES

Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.

(2015) M. Casadellà et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

(2014) Maureen Oliveira et al.   AIDS

Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013

(2014) Joanne D Stekler et al.   ANTIVIRAL THERAPY

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance

(2014) Soundasse Munir et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

(2013) Karin J. Metzner et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

(2013) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen

(2012) Jaqueline Souza Cavalcanti et al.   ANTIVIRAL RESEARCH

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

(2012) F. Saladini et al.   CLINICAL MICROBIOLOGY AND INFECTION

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Evolution of raltegravir resistance during therapy

(2009) N. Sichtig et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

(2008) M KOBAYASHI et al.   ANTIVIRAL RESEARCH

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

(2008) O. Goethals et al.   JOURNAL OF VIROLOGY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE